Amber Tong
Asia Pharmaceuticals Reporter at Bloomberg News
Covering China biotech and pharma for Bloomberg News @business | formerly @endpts | views are my own | news and tips - [email protected]
Articles
-
6 days ago |
bloomberglinea.com | Amber Tong |Carsten Snejbjerg
Bloomberg — Un medicamento contra la obesidad procedente de China ayudó a los pacientes a perder mucho peso en un ensayo clínico de última etapa, lo que lo convierte en un nuevo rival potencial para los éxitos de taquilla de Novo Nordisk A/S y Eli Lilly & Co.Hangzhou Sciwind Biosciences Co. afirmó que su fármaco, la ecnoglutida, provocó una pérdida de peso superior al 15% tras 48 semanas cuando se administró en la dosis más alta.
-
1 week ago |
sg.finance.yahoo.com | Sangmi Cha |Winnie Hsu |Amber Tong
Sangmi Cha, Winnie Hsu and Amber Tong / Bloomberg Sat, 14 June 2025 at 9:17 pm GMT-4 4 min read The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s breakthrough artificial-intelligence app in January China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains.
-
1 week ago |
bloomberg.com | Sangmi Cha |Winnie Hsu |Amber Tong
(Bloomberg) -- China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector’s appeal.
-
2 weeks ago |
phillytrib.com | Amber Tong
A drug developed using artificial intelligence showed signs of efficacy in treating an incurable lung disease in what its developer calls a clinical first. Insilico Medicine, the biotech company with twin headquarters in Boston and Hong Kong, said it’s the first time an AI-created drug, working on an approach identified by AI, passed a mid-stage clinical study.
-
2 weeks ago |
bloomberg.com | Amber Tong
Local and international medical experts have since questioned how effective it really is in slowing or reversing the cognitive declines of Alzheimer’s patients given the relatively short duration of — and the inconsistent results shown in — its late-stage clinical trial in China.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 4K
- DMs Open
- Yes
Remember Green Valley Pharmaceutical, the Chinese company that earned an approval for a homegrown Alzheimer’s drug out of nowhere in 2019? It has halted production and sales after the drug's license expired, pending renewal -- https://t.co/86CKHGuq8u
RT @ByMadeleineA: $AMGN gets one over on $ZLAB in DLL3. Via @ApexOnco #ASCO25 https://t.co/R2tGGOtKR5
More deals: Regeneron licenses GLP-1/GIP receptor agonist from Hansoh for $80 million upfront https://t.co/wUU0KTpN3n